02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
16:53 , Aug 18, 2017 |  BioCentury  |  Emerging Company Profile

Teasing out Th1

EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation. Like most cancer vaccines in...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

PF-06671008: Phase I started

MacroGenics said Pfizer began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial of PF-06671008 in about 110 patients with tumors that potentially express CDH3. The start triggered a $2 million milestone payment to MacroGenics from...
08:00 , Dec 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Cadherin 1, type 1, E-cadherin (CDH1); cadherin 3, type 1, P-cadherin (CDH3); hepatocyte nuclear factor 4a (HNFA); laminin b1 (LAMB1) Genomewide association studies...
07:00 , Jun 30, 2008 |  BioCentury  |  Strategy

Pfizer’s biotherapeutic pipeline

Pfizer’s biotherapeutic pipeline...